Role of monoclonal antibody drugs in the treatment of COVID-19  

作　　者：Claudio Ucciferri Jacopo Vecchiet Katia Falasca 

机构地区：[1]Clinic of Infectious Diseases,Department of Medicine and Science of Aging,University“G.d'Annunzio”Chieti-Pescara,Chieti 66100,Italy [2]Department of Medicine and Health Sciences,University of Molise,Campobasso 66100,Italy

出　　处：《World Journal of Clinical Cases》2020年第19期4280-4285,共6页世界临床病例杂志

摘　　要：Currently clinicians all around the world are experiencing a pandemic caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2).The clinical presentation of this pathology includes fever,dry cough,fatigue and acute respiratory distress syndrome that can lead to death infected patients.Current studies on coronavirus disease 2019(COVID-19)continue to highlight the urgent need for an effective therapy.Numerous therapeutic strategies have been used until now but,to date,there is no specific effective treatment for SARS-CoV-2 infection.Elevated inflammatory cytokines have been reported in patients with COVID-19.Evidence suggests that elevated cytokine levels,reflecting a hyperinflammatory response secondary to SARS-CoV-2 infection,are responsible for multi-organ damage in patients with COVID-19.For these reason,numerous randomized clinical trials are currently underway to explore the effectiveness of biopharmaceutical drugs,such as,interleukin-1 blockers,interleukin-6 inhibitors,Janus kinase inhibitors,in COVID-19.The aim of the present paper is to briefly summarize the pathogenetic rationale and the state of the art of therapeutic strategy blocking hyperinflammation.

关 键 词：TOCILIZUMAB ANAKINRA CANAKINUMAB RUXOLITINIB Clazakizumab Siltuximab Sarilumab Baricitinib Tofacitinib 

分 类 号：R563.1[医药卫生—呼吸系统]